Analysis of DNA methylation in cancer: location revisited
Analysis of DNA methylation in cancer: location revisited
复制标题
DOI：
10.1038/s41571-018-0004-4
复制
发表时间：
2018-07-01
影响因子：
78.8
通讯作者：
van Engeland, Manon
中科院分区：
文献类型：
--
作者：
Koch, Alexander;Joosten, Sophie C.;van Engeland, Manon
癌症中DNA甲基化的变化被认为是开发强大的诊断、预后和预测生物标记物的有希望的靶点。尽管有14,000多篇描述基于DNA甲基化的生物标记物及其在癌症中的临床相关性的科学出版物，但这些生物标记物中只有14个被转化为商业上可用的临床试验。方法和实验障碍都是造成这种差异的主要原因，但基于DNA甲基化的生物标记物的基因组位置是一种内在和必要的属性，也具有重要而经常被忽视的作用。在这里，我们检查了DNA甲基化位置对癌症生物标记物开发的重要性，并通过商业可用的测试详细地查看了各种生物标记物的基因组位置和其他相关特征。我们还强调公开可用的数据库对于开发基于DNA甲基化的生物标记物的价值，以及准确报告研究结果的全部方法学细节的重要性。
Changes in DNA methylation in cancer have been heralded as promising targets for the development of powerful diagnostic, prognostic, and predictive biomarkers. Despite the existence of more than 14,000 scientific publications describing DNA methylation-based biomarkers and their clinical associations in cancer, only 14 of these biomarkers have been translated into a commercially available clinical test. Methodological and experimental obstacles are both major causes of this disparity, but the genomic location of a DNA methylation-based biomarker is an intrinsic and essential property that also has an important and often overlooked role. Here, we examine the importance of the location of DNA methylation for the development of cancer biomarkers, and take a detailed look at the genomic location and other relevant characteristics of the various biomarkers with commercially available tests. We also emphasize the value of publicly available databases for the development of DNA methylation-based biomarkers and the importance of accurate reporting of the full methodological details of research findings.